Glivec case final hearing in India rescheduled for Sept
This article was originally published in Scrip
The Indian patent case concerning Novartis' anticancer, Glivec (imatinib mesylate), and its rejection due to a controversial provision in India's patent law, will now come up for hearing in the Supreme Court only in September.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.